Cancer
Malignant Rectal Neoplasm
CI-CAN-00008012Explore in graph →
Top-level388 active trials1 approved drugs5 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer
CI-CAN-00008012Explore in graph →
Clinical trials
1,551 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (153)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04963283 | Study of Cabozantinib and Nivolumab in Refractory Metastatic Microsatellite Stable (MSS) Colorectal Cancer | active not recruiting | Phase 2 | 48 | University of Colorado, DenverOTHER | 1 | Mar 31, 2026 | clinicaltrials |
| NCT05806931 | Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer(SCOTI) | recruiting | Phase 2 | 50 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 18, 2026 |
| clinicaltrials |
| NCT07469306 | Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 130 | Fujian Cancer HospitalOTHER_GOV | 1 | Mar 13, 2026 | clinicaltrials |
| NCT07458529 | Neoadjuvant Chemoradiotherapy Plus Tislelizumab With or Without Probio-M9 in pMMR/MSS Locally Advanced Rectal Cancer(NCRIT-PM9) | recruiting | Phase 2 | 50 | Seventh Medical Center of PLA General HospitalOTHER | 1 | Mar 10, 2026 | clinicaltrials |
| NCT05731726 | Serplulimab Combined With CAPEOX + Celecoxib as Neoadjuvant Treatment for Locally Advanced Rectal Cancer | recruiting | Phase 2 | 50 | Zhejiang UniversityOTHER | 1 | Mar 5, 2026 | clinicaltrials |
| NCT06608537 | A Clinical Study Based on FAPI-PET/CT Technology to Predict Pathological Complete Response After Neoadjuvant Chemoradiotherapy for MSS Rectal Cancer | completed | Phase 2 | 52 | Sun Yat-sen UniversityOTHER | 1 | Mar 4, 2026 | clinicaltrials |
| NCT07223567 | A Trial of Regorafenib Plus Lorigerlimab in Patients With Locally Recurrent or Regrowing pMMR/MSS Localized Rectal Cancer | withdrawn | Phase 2 | 0 | M.D. Anderson Cancer CenterOTHER | 0 | Feb 25, 2026 | clinicaltrials |
| NCT07337876 | Organ Preservation in Rectal Cancer by Dose Escalated MR Guided Adaptive Radiotherapy(MARS) | recruiting | Phase 2 | 100 | University Hospital TuebingenOTHER | 1 | Feb 17, 2026 | clinicaltrials |
| NCT07407465 | Upfront Trastuzumab-Deruxtecan Plus Capecitabine and Bevacizumab for Patients With HER-2 Positive Metastatic Colorectal Cancer.(CHIMERA) | recruiting | Phase 2 | 42 | Gruppo Oncologico del Nord-OvestOTHER | 4 | Feb 17, 2026 | clinicaltrials |
| NCT05673772 | Preoperative Sequential Short-course Radiation Therapy and FOLFOX for Locally Advanced Rectal Cancer(SOLAR) | active not recruiting | Phase 2 | 364 | Kyungpook National University HospitalOTHER | 1 | Feb 12, 2026 | clinicaltrials |
| NCT03516708 | Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer | recruiting | Phase 1 / Phase 2 | 49 | Washington University School of MedicineOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07397442 | Short-Course Radiotherapy Combined With Chemotherapy and Immunotherapy in Mid-Low Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 | 19 | Beijing Friendship HospitalOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT07402486 | A Phase II Prospective Study of Maastro Applicator Brachytherapy for Rectal Cancer | not yet recruiting | Phase 2 | 20 | Siriraj HospitalOTHER | 0 | Feb 11, 2026 | clinicaltrials |
| NCT03365882 | S1613, Trastuzumab and Pertuzumab or Cetuximab and Irinotecan Hydrochloride in Treating Patients With Locally Advanced or Metastatic HER2/Neu Amplified Colorectal Cancer That Cannot Be Removed by Surgery | completed | Phase 2 | 240 | SWOG Cancer Research NetworkNETWORK | 2 | Feb 10, 2026 | clinicaltrials |
| NCT04109924 | TAS-102, Irinotecan, and Bevacizumab for the Treatment of Pre-treated Metastatic or Unresectable Colorectal Cancer, the TABAsCO Study | completed | Phase 2 | 42 | Roswell Park Cancer InstituteOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT07394192 | Short-Course Radiotherapy With Tumor-Draining Lymph Node Preservation Followed by PD-1 Inhibitors in pMMR/MSS Stage II-III Rectal Cancer(PKUCH- R11) | not yet recruiting | Phase 2 | 44 | Peking University Cancer Hospital & InstituteOTHER | 0 | Feb 6, 2026 | clinicaltrials |
| NCT07381400 | Neoadjuvant mFOLFOX6 Chemotherapy Combined With Anti-PD-1 Therapy in MSS/pMMR Locally Advanced Rectal Cancer (FIRM02 Study) | not yet recruiting | Phase 2 | 128 | Xinhua Hospital, Shanghai Jiao Tong University School of MedicineOTHER | 0 | Feb 3, 2026 | clinicaltrials |
| NCT06710847 | A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Effectiveness of GSK4418959 Alone or in Combination With Other Anti-cancer Agents in Participants With Solid Tumors(SYLVER) | active not recruiting | Phase 1 / Phase 2 | 14 | GlaxoSmithKlineINDUSTRY | 7 | Feb 2, 2026 | clinicaltrials |
| NCT07381777 | XELOX Plus DoSTARlimab Versus XELOX Alone as Consolidation Treatment After Standard Chemoradiation in pMMR/MSS or MSI-Low Locally Advanced Rectal Cancer (LARC) Patients(IMMUNOSTAR) | not yet recruiting | Phase 2 | 270 | Gruppo Oncologico Italiano di Ricerca ClinicaOTHER | 1 | Feb 2, 2026 | clinicaltrials |
| NCT04505553 | Oral Cryotherapy Plus Acupressure and Acupuncture Versus Oral Cryotherapy for Decreasing Chemotherapy-Induced Peripheral Neuropathy From Oxaliplatin-Based Chemotherapy in Patients With Gastrointestinal Cancer | completed | Phase 2 | 78 | University of WashingtonOTHER | 1 | Jan 21, 2026 | clinicaltrials |
| NCT00826540 | Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer | completed | Phase 2 | 83 | Alliance for Clinical Trials in OncologyOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT07347951 | A Single-center, Phase II Study on Efficacy & Safety of SCRT+CAPOX+Serplulimab+Bevacizumab for MSS Rectal Cancer | recruiting | Phase 2 | 30 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Jan 16, 2026 | clinicaltrials |
| NCT06864013 | SCRT Combined With Chemotherapy and Iparomlimab and Tuvonralimab in MSS or pMMR Patients With Locally Advanced Rectal Cancer | recruiting | Phase 2 | 116 | First Affiliated Hospital of Zhejiang UniversityOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal Cancer | recruiting | Phase 2 / Phase 3 | 375 | Beijing Friendship HospitalOTHER | 1 | Jan 13, 2026 | clinicaltrials |
| NCT07321847 | Injection of IP-001 Into Thermally Ablated Hepatic Tumors in Patients With Colorectal Liver Metastases(INJECTABL-3) | not yet recruiting | Phase 2 / Phase 3 | 717 | Immunophotonics, Inc.INDUSTRY | 0 | Jan 7, 2026 | clinicaltrials |
| NCT07068763 | Node-Sparing Short-Course Radiation Combined With Capecitabine and PD-1/CTLA-4 for MSS Early Rectal Cancer(mRCAT-E) | recruiting | Phase 2 | 52 | Sir Run Run Shaw HospitalOTHER | 1 | Jan 6, 2026 | clinicaltrials |
| NCT03921684 | Trial of Nivolumab With FOLFOX After Chemoradiation in Rectal Cancer Patients | active not recruiting | Phase 2 | 29 | Baruch BrennerOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT07314528 | Evaluating the Impact of GLP-1 Receptor Agonists With Total Neoadjuvant Therapy in Rectal Cancer | not yet recruiting | Phase 2 | 42 | St. James's Hospital, IrelandOTHER | 0 | Jan 2, 2026 | clinicaltrials |
| NCT07297030 | SIB-RT Combined With CAPOX and PD-1 for High-Risk Rectal Cancer | not yet recruiting | Phase 2 | 37 | Sun Yat-sen UniversityOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07284992 | SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC | recruiting | Phase 2 | 208 | Shandong Provincial HospitalOTHER_GOV | 1 | Dec 16, 2025 | clinicaltrials |
| NCT04417699 | SHOrt Course Radiation and TASOX (TAS102 Plus Oxaliplatin) Chemotherapy in Operable Rectal Cancer(SHORT) | completed | Phase 2 | 13 | Providence Health & ServicesOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02921256 | Veliparib, Pembrolizumab, and Combination Chemotherapy in Treating Patient With Locally Advanced Rectal Cancer | completed | Phase 2 | 363 | National Cancer Institute (NCI)NIH | 2 | Dec 4, 2025 | clinicaltrials |
| NCT05358704 | Preoperative ChemoRadiation And FOLFOXIRI for Rectal Cancer (CRAFTER) for Rectal Cancer | suspended | Phase 2 | 38 | Rutgers, The State University of New JerseyOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06493240 | Neoadjuvant Long-course Chemoradiotherapy Followed by Immunotherapy for Locally Advanced Mid-low Rectal Cancer(NLCCRIT-LARC) | completed | Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07248020 | A Phase II Single-Arm Study of High-Bioavailability Curcumin as Neoadjuvant Chemoradiotherapy in Mid-to-Low Rectal Cancer: Integrated Clinical and Translational Analysis of Tumor Tissue(BCMRECRAD) | not yet recruiting | Phase 2 | 72 | Chang Gung Memorial HospitalOTHER | 1 | Nov 25, 2025 | clinicaltrials |
| NCT07243938 | Phase II Basket Trial: Zanidatamab Plus Tislelizumab in HER2-Positive GI Tumors (UNION-HER2-BASKET) | not yet recruiting | Phase 2 | 70 | Tao ZhangOTHER | 0 | Nov 24, 2025 | clinicaltrials |
| NCT07127497 | Clinical Study on the Safety and Relationship of Sintilimab Combined With Chemotherapy in Neoadjuvant Treatment of Locally Advanced Rectal Adenocarcinoma | active not recruiting | Phase 2 | 50 | The First Affiliated Hospital of Anhui Medical UniversityOTHER | 1 | Nov 21, 2025 | clinicaltrials |
| NCT01941641 | Colon Neoadjuvant FOLFOXIRI Study | active not recruiting | Phase 2 | 40 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03997435 | FOLFOXIRI With or Without Intensification for Rectal Cancer | active not recruiting | Phase 2 | 72 | CCTUOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07198165 | SCRT Followed by CAPOX + Bev ± PD-1 Inhibitor for TNT in LARC | recruiting | Phase 2 | 104 | Ruijin HospitalOTHER | 1 | Sep 30, 2025 | clinicaltrials |
| NCT07175636 | QL1706 With Short-Course Radiotherapy and Chemotherapy for MSS Rectal Cancer | not yet recruiting | Phase 2 | 66 | Sun Yat-sen UniversityOTHER | 0 | Sep 16, 2025 | clinicaltrials |
| NCT07161115 | Involve-site Radiotherapy Combined With Chemotherapy and Immunotherapy as Neoadjuvant Treatment for Locally Advanced Rectal Cancer(REFIRT) | not yet recruiting | Phase 2 | 60 | Longhao LiOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT06682793 | A Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated CAR T, in Participants With Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression(DENALI-1) | recruiting | Phase 1 / Phase 2 | 240 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Sep 9, 2025 | clinicaltrials |
| NCT06770270 | Pucotenlimab Plus Radiotherapy and Chemotherapy for Neoadjuvant Treatment of Locally Advanced Rectal Cance(PUCRT)(PUCRT) | recruiting | Phase 2 | 68 | Second Affiliated Hospital, Zhejiang University, School of MedicineOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT07150949 | Long-course Chemoradiotherapy or Short-course Radiotherapy Combined With CAPOX, PD-1antibody, and COX-2 Inhibitor for MSS Locally Advanced Rectal Cancer (SERRAC) | recruiting | Phase 2 | 138 | Fudan UniversityOTHER | 1 | Sep 2, 2025 | clinicaltrials |
| NCT05576480 | SCRT Sequential Penpulimab in Combination With CAPEOX in the Neoadjuvant Treatment of MSS Locally Advanced Rectal Cancer(SPARC) | recruiting | Phase 2 | 55 | Ruijin HospitalOTHER | 1 | Aug 28, 2025 | clinicaltrials |
| NCT07134218 | Neoadjuvant Chemoradiotherapy Combined With Immunotherapy and Anti-angiogenesis in Treating Locally Advanced Rectal Cancer | not yet recruiting | Phase 2 / Phase 3 | 180 | Changhai HospitalOTHER | 1 | Aug 21, 2025 | clinicaltrials |
| NCT05732389 | Immunotherapy in Patients With Early dMMR Rectal Cancer(RESET-R) | recruiting | Phase 2 | 39 | Odense University HospitalOTHER | 1 | Aug 7, 2025 | clinicaltrials |
| NCT07108127 | Efficacy and Safety of Trastuzumab Biosimilars and Pertuzumab Biosimilars Combined With Chemotherapy for Neoadjuvant Treatment of Patients With Locally Advanced HER2-positive Rectal Cancer(NePHera) | recruiting | Phase 2 | 24 | Peking Union Medical College HospitalOTHER | 1 | Aug 6, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Mar 31, 2026source: clinicaltrials